SNSS will be giving an update on some of their drug products that are in various phases of development. L-1 in particular, and an update on the pan-Raf kinasis inhibitor progress, according to Eric Bjerkholt.
The stock will rise on the good news presented as these drug products going further along in their Phases.
If you listen to the UBS Global Healthcare Services Conference call on the Sunesis web site, you will hear Eric say that the results will be presented at ASCO. I'm just repeating what I heard on the call.